Elektrofi has entered a partnership with ImmunoPrecise Antibodies (IPA) for developing a high-concentration formulation of the latter’s Covid-19 antibody cocktail, PolyTope TATX-03. 

The alliance intends to produce a data package required for filing an investigational new drug (IND) application with the Food and Drug Administration (FDA) for TATX-03E, an alternative formulation of TATX-03, that could be administered by oneself in the non-healthcare setting. 

TATX-03E could potentially tackle the requirements for deployment-ready, low-volume, stable, self-injectable formulation.

By combining the efforts, the companies plan to formulate TATX-03E for a stable and quick consumer supply.

This drug product will be developed to be well suited to meet unmet needs for field usage, quick deployment and increased dosing frequency for immunocompromised people who need continued access to treatments and prophylaxis.

In the initial stage, IPA and Elektrofi will commence formulation feasibility studies and subsequent IND-enabling, non-clinical studies to validate the safety and efficacy of TATX-03’s new formulation.

Elektrofi’s agreement with the US Department of Defense’s (DoD) Defense Health Agency (DHA) Small Business Innovation Research (SBIR) Program will support the collaboration between the companies.

Elektrofi Scientific Strategy director Daniel Dadon said: “We are impressed by the neutralising activity demonstrated by ImmunoPrecise’s antibody cocktail against current variants of concern, including Omicron. 

“Nearly all other programmes we have looked into partnering with do not demonstrate the ability to neutralise so many variants. 

“We look forward to working with IPA to develop a product that could potentially improve access to this class of life saving medicines and reduce the burden on healthcare systems.” 

In February 2020, IPA commenced a research programme to develop a vaccine and therapeutic antibodies for Covid-19.